

Design and Synthesis of Peptide Modulators of $G\alpha_i/s$ Proteins

Anna Pepanian¹, Sabriye Aydoğdu¹, F. Ayberk Binbay¹, Pradipta Ghosh², Dehua Pei³, and Diana Imhof¹

¹Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, Bonn, Germany, ²Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, USA, ³Department of Chemistry and Biochemistry, The Ohio State University, Columbus, USA.

Introduction

The stimulation of G protein-coupled receptors (GPCRs) by ligand binding initiates the shuttle of heterotrimeric G proteins ($G\alpha\beta\gamma$) between the active ($G\alpha$ -GTP) and inactive ($G\alpha$ -GDP) state¹. Subsequently, the active $G\alpha$ -GTP subunit and the $G\beta\gamma$ dimer interact with downstream effectors that trigger several intracellular pathways. These can provoke cellular alterations that account for severe diseases. Such cellular changes can be investigated through peptides targeting specifically the $G\alpha$ subunits²⁻³. For instance, the discovery of the macrocyclic depsipeptides YM-254890 and FR900359, inhibitors of the $G\alpha_q$ subfamily, evoked curiosity in developing linear and cyclic peptides against other $G\alpha$ subunits. Interestingly, procedures such as the screening of **combinatorial peptide libraries** revealed the KB-752, GIV-Girdin, and GPM-1c/d (G protein modulator) peptides, which exhibit novel GEM (guanine nucleotide exchange modulator)-like activities by inhibiting $G\alpha_i$ and activating the $G\alpha_s$ signaling cascades³⁻⁹.

Workflow






Figure 1. The methodology includes (1) peptide library screening, (2) synthesis, (3) binding analysis, (4) cellular activity assays, and (5) computational modeling and docking studies. Created with BioRender.com.

Results

- We previously identified a linear nonapeptide, GPM-1, from the screening of a one-bead-one-compound (OBOC) library against $G\alpha_i$ -GDP³⁻⁵, which revealed high binding affinities to $G\alpha_i$ and $G\alpha_s$, resulting in a bifunctional GEM-like activity. Chemical modifications of the GPM-1 lead compound, such as cyclization and conjugation with a cell-penetrating peptide (series GPM-1b/c/d), resulted in modulators with enhanced proteolytic stability and cell permeability.
- Second, an advanced **one-bead-two-compound (OBTC)** library was screened towards both activity states of the $G\alpha_i$ protein and revealed bicyclic peptides containing non-proteinogenic and D-amino acids (GPM-2, GPM-3, peptide 10, (Fig. 2a-c)). Cellular studies showed that the GPM-2/3 compounds bind to novel sites on the protein surface influencing thereby their biological properties (GPM-2 as GEF-like and GPM-3 as a GAP-like modulator of the $G\alpha_i$ signaling (Fig. 2d)).



- In silico* studies of the peptides GPM-2, GPM-3, and peptide 10 defined the structural similarities and differences between them (Fig. 3a, b). Protein-ligand docking studies also revealed similarities in the binding site between peptide 10 and GPM-3, which were found to interact between the α -helical and switch III region (SWIII) (Fig. 3a).



- Despite the binding site similarity, the K_D value (9.077 μ M) was higher for peptide 10 compared to GPM-2 (5.0 μ M) and GPM-3 (0.7 μ M) (Fig. 2d). The reduced binding affinity may be a result of the positioning of the high numbers of hydrogen bond donor and acceptor residues (Lys, Thr, Tyr, Dap).
- Additionally, the interaction of both rings of peptide 10 with the protein might introduce unfavorable interactions, contributing to the overall weaker binding affinity.

Summary & Outlook

Our studies with different combinatorial peptide libraries revealed novel $G\alpha_i/s$ modulators with distinct guanine nucleotide exchange activities. Compounds GPM-2, GPM-3, and peptide 10 were identified from an OBTC peptide library with promising selectivity for $G\alpha_i$. *In silico* studies unveiled new important structural features for $G\alpha_i$ binding, which were confirmed by comparison of peptide 10 to the $G\alpha_i$ modulators GPM-2 and GPM-3. These findings provide fundamental knowledge for deeper investigations of peptide 10, and optimization of the biological properties of the obtained compounds to achieve higher pharmacological potencies.

References

- Campbell et al. *Nat. Rev. Drug Discov.*, (2018), 17(11), 789-803
- Johnston et al. *FEBS Letters*, (2005), 579(25), 5756-5750
- Nubbemeyer et al. *ACS Chem. Biol.*, (2022), 17(2), 463-473
- Pepanian et al. *J. Med. Chem.*, (2023), 66(17), 12396-12406
- Pepanian et al. *J. Pept. Sci.*, (2024), 30(6), e3565
- Upadhyaya et al. *Tetrahedron*, (2014), 70(42), 7714-7720
- Kalogriopoulos et al. *PNAS*, (2019), 116(33), 16394-16403
- Lian et al. *JACS*, (2014), 136(28), 9830-9833
- Coleman et al. *Science* (1994), 265, 1405-1412

Acknowledgment

DFG Deutsche Forschungsgemeinschaft
heinchertzstiftung

DAAD Deutscher Akademischer Austauschdienst
German Academic Exchange Service
GDCh

Check Imhof Lab Publications

